Neuronetrix announces preliminary study results for COGNISION System to diagnose Alzheimer’s
Codexis, Inc. today announced a licensing agreement with Teva Pharmaceutical Industries Ltd., to produce an important publicly-undisclosed generic product, using a proprietary Codexis biocatalyst. Teva, the largest generic drug manufacturer in the world, is a leading producer of this generic product. The product is one of the largest- selling generic prescription drugs in the United
Full Post: Codexis announces licensing agreement with Teva Pharmaceutical Industries
Last week, at the Society for Neuroscience Conference in Washington DC, Neuronetrix announced preliminary results from a clinical study of their COGNISION System to diagnose Alzheimer’s disease.
The study was performed with Alzheimer’s patients at the University of Kentucky’s Sanders-Brown Center for Aging.
The COGNISION System uses event-related potentials (ERP) to record brain activity while the patient listens to a sequence of sounds. Subjects with Alzheimer’s process auditory information differently than healthy individuals and that difference can be detected with the test.
The ability of the ERP method to diagnose Alzheimer’s disease has been demonstrated in scientific studies at several research laboratories around the world. In a scientific paper published in 2007, Neuronetrix collaborators Drs. Robi Polikar, et al, reported that their ERP classification accuracy “exceeded that of the trained community clinic physicians, and closely approached the gold standard performance of the university hospital-based clinic evaluation.”
This phase of the study was primarily performed to evaluate the COGNISION System in a real-world clinical setting to test ease of use, patient tolerance, and most importantly, data quality.
“Clinical usability and technical performance were major milestones in our study at the Sanders-Brown Center.” “The system exceeded our expectations in terms of data quality and we demonstrated the test could be efficiently performed on real Alzheimer’s patients.” K.C. Fadem, Neuronetrix, Inc.
The next clinical study phase for Neuronetrix will be to test the COGNISION System in a multi-center trial on patients who have been diagnosed with Alzheimer’s disease using a rigorous diagnostic protocol. This protocol will be similar to that used in the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a large international study sponsored by the US National Institutes of Health (NIH).
The ADNI protocol uses psychometric testing, magnetic resonance imaging (MRI), and cerebrospinal fluid analysis (CSF) to accurately characterize several aspects of Alzheimer’s disease. Neuronetrix will use these same tests to correlate with the COGNISION ERP results.
“We want to compare our COGNISION System with the most advanced diagnostic methods possible to clearly demonstrate the system’s capabilities.” Dr. John Barker, Chairman, Neuronetrix, Inc.
Neuronetrix is currently working with several NIH Center’s of Excellence in the US and a center in Europe to organize the study which is expected to begin in the first quarter of 2009.
MRI scans that detect shrinkage in specific regions of the mid-brain attacked by Alzheimer’s disease accurately diagnose the neurodegenerative disease, even before symptoms interfere with daily function, a study by the Florida Alzheimer’s Disease Research Center (ADRC) in Miami and Tampa found. The study, reported earlier this month in the journal Neurology, adds to a
Full Post: MRI brain scans provide valuable diagnostic information about Alzheimer’s
GE Healthcare continues to re-invent and re-imagine cardiology and the innovations that may help fuel the field through the future. At the 2008 Scientific Sessions of the American Heart Association, in New Orleans this week, the company plans to showcase new products, new relationships and, above all, a new way to look at clinical practice.
Full Post: GE Healthcare showcases new cardiology technology
Scientists say brain scans show that education appears to lessen the effects of Alzheimer’s disease. The scientists from the Washington University School of Medicine, St. Louis, say their research supports the ‘cognitive reserve’ hypothesis and individuals with levels of higher education levels score higher on cognitive tests despite having Alzheimer’s disease. According to the hypothesis,
Full Post: Education lessens the effects of Alzheimer’s
One quarter of all family caregivers of Alzheimer’s disease patients succumb to the stress of providing care to a loved one and become hospital patients themselves, according to an Indiana University study published in the November 2008 issue of the Journal of General Internal Medicine. Researchers from the Indiana University School of Medicine, the
Full Post: Study finds 25% of family caregivers of AD patients go to ER or are hospitalized
Individuals with higher education levels appear to score higher on cognitive tests despite having evidence of brain plaques associated with Alzheimer’s disease, according to a report in the November issue of Archives of Neurology. The cognitive reserve hypothesis holds that individuals with greater cognitive (thinking, learning and memory) abilities are able to delay symptoms of
Full Post: Greater thinking, learning and memory abilities delay symptoms of Alzheimer’s disease